Pharmacolog’s distributor has ordered a first system to be placed at Hôspital du Confluent in Nantes. The system shall be used for the final control of chemotherapy drugs toxicity at the hospital pharmacy. Pharmed won the order in competition with other suppliers.
During 2016, Pharmed has deliberately processed the French market, focusing on hospital pharmacies that prepare for chemotherapy and has now placed the first order on a DrugLog system. The system will be placed at the Hôspital du Confluent in Nantes and will be used for the final control of chemotherapy drugs prepared made at the hospital pharmacy. The deal means that, according to agreement, Pharmed purchases a DrugLog® systems from Pharmacolog for delivery to the hospital and results in a certain turnover impact.
CEO Mats Högberg comments: “It is extremely pleasing that Pharmed managed to get his first order. Key benefits that played an important role for the decision was DrugLog’s speed and ease of use. Then, of course, it’s extra satisfying to win a deal where we competed against a domestic French competitor. The deal is a result of the purposeful and long-term work of our Pharmed distributor, which is now beginning to show results. ”
Didier Dubois, Sales Manager at Pharmed SAM: “We have been working methodically in introducing the DrugLog concept in France and are very happy to be able to close our first deal. The interest for DrugLog is increasing and our sales funnel steadily growing. There is definitely a strong demand for efficient solutions for validation of chemo drugs in the French market so we have great hope that Nantes will be followed by many others.”
Extended collaboration with Uppsala University regarding dosage of antibiotics
Pharmacolog AB enters a new research and development cooperation with researchers from Uppsala University regarding methods for determining antibiotic concentration in the blood. The agreement is a direct continuation of the agreement signed in spring 2017, which runs until the end of the year.
The project carried out to date has been very successful and has shown that Pharmacolog’s technology can detect very small concentrations of antibiotics in blood. The parties have therefore decided to continue the cooperation with purpose to develop a clinical prototype for patient-related control of antibiotic levels in blood by 2018.
Hans Dahlin, Research Director and Founder, comments: R...
The study conducted at the University Hospital in Lille with DrugLog in order to control drug preparations carried out in the operating room has now been completed. A total of 22 different drugs were checked and the result indicated an error rate in the drug preparations of 6.9%.
The study, conducted during the summer, was part of a doctoral thesis and the results were presented in connection with the dissertation at the Pharmacy Department earlier this fall. Of the 232 analyzes analyzed, it was found that 6.9% had a concentration beyond the tolerance level. According to the study, the cost of an error medication is about 4,000 €, which means that DrugLog control in these cases potentially result...
DrugLog® will be evaluated by a hospital chain in New York
Pharmacolog and one of New York’s most reputable hospital chains have signed an agreement that DrugLog® should be evaluated at two of the organization’s hospitals for use in a Drug Diversion program. The hospital chain pays for the evaluation scheduled to start in December and is expected to be completed in the first quarter of 2018.
Theft of narcotic intravenous drugs in healthcare is an growing problem. In the US, the authorities have initiated various preventive actions as the abuse of opiates reaches alarming levels. Since DrugLog can identify such drugs and also see if they have been manipulated in any way, DrugLog is a useful tool to prevent this development. The interest in usi...
Pharmacolog i Uppsala AB (publ) har genomfört en nyemission med företrädesrätt för befintliga aktieägare med teckningstid 27 september – 13 oktober 2017 efter beslut av styrelsen den 28 augusti med stöd av bemyndigande från Bolagets årsstämma den 3 maj 2017. Emissionen, som övertecknades, tillförde Bolaget 19,6 MSEK före emissionskostnader.
Emissionen har registrerats av Bolagsverket den 1 november 2017. I samband med att emissionen har registrerats av Bolagsverket kommer betalda tecknade aktier (BTA) att avregistreras och ersättas av nya aktier. Sista dag för handel med BTA på Aktietorget är den 6 november 2017.
Genom nyemissionen har aktiekapitalet i Pharmacolog ökat med 1 178 799,90 SEK...